Methylpyrrole inhibitors of BET bromodomains
Lisa Hasvold(AbbVie (United States)), Keith F. McDaniel(AbbVie (United States)), Yu Shen(University of Florida), Sanjay C. Panchal(AbbVie (United States)), Daniel H. Albert(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Scott E. Warder(AbbVie (United States)), Chang H. Park(AbbVie (United States)), Terrance J. Magoc(AbbVie (United States)), Dachun Liu(Kunming University of Science and Technology), Carol K. Wada(AbbVie (United States)), Leiming Li(First Hospital of China Medical University), George S. Sheppard(AbbVie (United States)), Nirupama B. Soni(AbbVie (United States)), Robert A. Mantei(AbbVie (United States)), Warren M. Kati(AbbVie (United States)), Andrew M. Petros(Abbott Fund), Lauren Smithee(AbbVie (United States)), Robbert Hubbard(AbbVie (United States)), John K. Pratt(AbbVie (United States)), Xiaoyu Lin(AbbVie (United States)), Le Wang(Rutgers, The State University of New Jersey), Xiaoli Huang(Sichuan Agricultural University), Steven W. Elmore(AbbVie (United States)), Steven D. Fidanze(AbbVie (United States)), Chaohong Sun(AbbVie (United States)), Denise Wilcox(Abbott (United States)), Peter Kovar(AbbVie (United States))
Cited by 19
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k